The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index; none of the 49 sources its claims cite is checked for support yet.
Pre‐clinical properties of the α4β2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence
Open accessAbstract
Background and purpose: Smoking cessation trials with three high‐affinity partial agonists of α4β2 neuronal nicotinic acetylcholine receptors (nAChRs) have demonstrated differences in their clinical efficacy. This work examines the origin of the differences by taking into account brain exposure and pharmacological effects at human α4β2 nAChRs. Experimental approach: Rat plasma and brain pharmacokinetics were characterized and used to predict human steady‐state plasma and brain concentrations following recommended doses of each of the three compounds. The pharmacological characterization included in vitro affinities at different nAChR subtypes, functional efficacies and potencies at the human α4β2 nAChR, as well as in vivo effects on rat mesolimbic dopamine turn‐over. Key results: A comparison of predicted human brain concentrations following therapeutic doses demonstrated that varenicline and nicotine, but not dianicline and cytisine, can extensively desensitize and, to a lesser extent, activate α4β2 nAChRs. The limited clinical efficacy of dianicline may be accounted for by a combination of weak functional potency at α4β2 nAChRs and moderate brain penetration, while recommended doses of cytisine, despite its high in vitro potency, are predicted to result in brain concentrations that are insufficient to affect α4β2 nAChRs. Conclusions and implications: The data provide a plausible explanation for the higher abstinence rate in smoking cessation trials following treatment with varenicline than with the two other α4β2 nAChR partial agonists. In addition, this retrospective analysis demonstrates the usefulness of combining in vitro and in vivo parameters with estimated therapeutic human brain concentrations for translation to clinical efficacy.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
This retrospective translational study compared varenicline, cytisine, and dianicline using rat pharmacokinetics, predicted human unbound brain concentrations, and in vitro/in vivo α4β2 nAChR pharmacology. It concludes that varenicline’s higher predicted brain exposure and functional potency at α4β2 nAChRs plausibly explain its greater clinical efficacy for smoking cessation than cytisine or dianicline.
Key findings
- Predicted human unbound steady-state brain concentrations after recommended doses were 32–131 nM for varenicline, 2–10 nM for cytisine, and 37–84 nM for dianicline; varenicline and nicotine were predicted to extensively desensitize and, to a lesser extent, activate α4β2 nAChRs, whereas cytisine was predicted to cause significant desensitization but not activation, and dianicline only minimal desensitization.
- At human α4β2 nAChRs, binding affinities were Ki 0.4 nM for varenicline, 2.0 nM for cytisine, and 105 nM for dianicline; agonist efficacies versus ACh were 22 ± 2.5% for varenicline, 6.5 ± 0.2% for cytisine, and 8.0 ± 0.3% for dianicline.
- In rat nucleus accumbens dopamine turnover, varenicline (ED20 ∼0.12 mg kg−1 p.o.) was about 20-fold more potent than cytisine (ED20 ∼2.5 mg kg−1) and at least 100-fold more potent than dianicline (ED20 ∼20 mg kg−1); partial agonists increased turnover to less than 140% of controls versus 180% for 1 mg kg−1 s.c. nicotine.
- Clinical context cited: varenicline OR 3.7 (95% CI 2.86–4.68) versus placebo; cytisine OR 1.9 (95% CI 1.2–3.1); dianicline phase 2 end-of-treatment quit rates 16% versus 8% for placebo.
Methods
- Rat and mouse pharmacokinetic/brain-disposition studies measured protein binding, plasma/brain/CSF/extracellular fluid exposures, ultra-slow-flow microdialysis, P-gp-deficient versus wild-type mice, and i.v./p.o. PK; human steady-state plasma and brain exposures were predicted by allometric scaling and rat brain-to-plasma ratios after recommended doses.
- In vitro pharmacology used radioligand binding at nAChR subtypes and two-electrode voltage clamp in Xenopus oocytes expressing human α4β2 nAChRs for activation/desensitization; in vivo rat nucleus accumbens dopamine turnover was measured by HPLC-EC after oral partial agonists versus 1 mg kg−1 s.c. nicotine.
- Samples included male Sprague-Dawley rats (n = 75), male FVB/N and mdr1a/1b knockout mice (n = 12 each), Xenopus females (n = 5), and dopamine turnover groups of n = 4–6.
Limitations
- Stated: no head-to-head clinical comparisons among the three partial agonists; dianicline data were preliminary phase 2 only and development was halted; further work is needed to evaluate other nAChR subtypes (e.g., α7, α3*, α5*, α6*) in varenicline’s effects.
- Stated/evident: human brain concentrations for cytisine and dianicline were predicted by allometric scaling from rat PK and assumed the same rat/human brain-to-plasma ratios, not directly measured; varenicline human plasma data came from prior reports.
- Evident: in vitro α4β2 experiments used a mixed receptor population not enriched for specific stoichiometry; microdialysis ECF exposures were lower than unbound brain estimates, and the paper notes possible overestimation of unbound brain exposure or active transport for nicotine/varenicline.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
43 Own result · 25 Not checked yet · 24 Own interpretation · 8 No basis given
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“It has 15-fold higher affinity than nicotine (Ki= 6.1 nM)”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“However, in brain, human steady-state unbound concentrations (Bu) after recommended doses of varenicline are predicted to be much higher than those of cytisine due to the reduced brain entry of cytisine (Table 2).”
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and that varenicline binds to the α4β2 subtype with higher receptor affinity (Ki= 0.4 nM) than the other compounds.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Other molecular properties that can affect brain penetration, such as ELogD7.4, polar surface area, membrane permeability, multidrug resistance protein (MDR1) and breast cancer resistance protein (BCRP) transporter susceptibility, do not significantly differ between the three partial agonists (Supporting Information Table S3).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“In this way, the unbound Css,avg in human brain after therapeutic doses was predicted to range from 32 to 131 nM for varenicline, from 2 to 10 nM for cytisine and from 37 to 84 nM for dianicline (Table 3).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- The authors state this as an assumption: Rat and human have the same brain-to-plasma ratio for each compound.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“while in addition, central exposures were 4- to 19-fold lower for dianicline and cytisine than for nicotine and varenicline.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“In this way, the unbound Css,avg in human brain after therapeutic doses was predicted to range from 32 to 131 nM for varenicline, from 2 to 10 nM for cytisine and from 37 to 84 nM for dianicline (Table 3).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- The authors state this as an assumption: Rat and human have the same brain-to-plasma ratio for each compound.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Each compound, in a dose-dependent manner, increased dopamine turn-over in rat nucleus accumbens.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“while varenicline is moderately protein bound (fu > 0.5) in plasma and brain (Table 1).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Cytisine is the only compound showing moderate affinity for the muscle α1-containing nAChRs (Ki= 430 nM) to which nicotine binds with low affinity (Ki= 2 µM), while varenicline and dianicline do not bind to this subtype (Ki values > 8 µM).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 29
- Probably not a substantial claim. 5
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“that dianicline is unbound in plasma and 60% bound in brain”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Following oral administration, both compounds were rapidly and fully absorbed into the systemic circulation as indicated by the short time to maximum plasma concentration (Tmax) (0.63 and 0.5 h) and complete oral bioavailability.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In vivo pharmacokinetic studies in rat demonstrated that oral administration of varenicline, cytisine or dianicline resulted in comparable unbound plasma exposures, but there are important differences between the unbound brain concentrations of the agents.”
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Rat single species allometry predicted that human unbound Css,avg after 1.5 mg QID cytisine was in the same range as reported values for unbound Css,avg after 1 mg BID varenicline, while 40 mg BID dianicline was estimated to result in a proportionally higher unbound Css,avg (Table 2).”
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Higher doses of the partial agonists were either poorly tolerated and not further assessed, or caused lower turn-over increases than after the previous test dose, resulting in an inverted U-shaped dose–response curve, consistent with previous findings (Rollema et al., 2007b).”
What the sources say
- Not checked yetcites Rollema et al., 2007b
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Cytisine is the only compound showing moderate affinity for the muscle α1-containing nAChRs (Ki= 430 nM) to which nicotine binds with low affinity (Ki= 2 µM), while varenicline and dianicline do not bind to this subtype (Ki values > 8 µM).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This concentration range between onset of activation and complete desensitization is approximately 10–100 µM for dianicline, and 0.01–10 µM for the other three compounds (Figure 3).”
- Also stated in: § Results · plain
“This pharmacologically relevant range between the activation and desensitization curves is 10–100 µM for dianicline, compared to 0.01–10 µM for nicotine, varenicline and cytisine (Figure 3).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Oral administration to rats of 1 mg kg–1 of each compound yielded comparable unbound plasma concentrations for the four compounds, with AUC0–6h values of 512, 397, 702 and 448 h ng–1 mL–1for nicotine, varenicline, cytisine and dianicline respectively.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These doses and unbound concentrations were for nicotine 1 mg kg–1 s.c. and ∼4 µM, for varenicline 1 mg kg–1 p.o. and ∼0.4 µM, for cytisine 10 mg kg–1 p.o. and ∼0.7 µM and for dianicline 20 mg kg–1 p.o. and ∼3.2 µM.”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although varenicline has significantly lower affinity for α7 (Ki= 125 nM) than for α4β2 nAChRs, it binds to this nAChR subtype with at least 20-fold higher affinity than the other compounds (Ki values > 2.1 µM).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Both compounds showed moderate volumes of distribution (Vd) with values ranging from 2.7 to 3.8 L kg–1, and short half-lives of 1.5 and 0.95 h respectively.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Measurements of unbound fractions (fu) of each of the four compounds show that nicotine and cytisine are essentially non-protein bound in plasma and brain (fu > 0.8)”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The EC50 values for high-affinity activation of α4β2 nAChRs ranged from 0.06 to 18 µM, while the IC50 values for high-affinity desensitization were 0.05–2.8 nM (Table 5, Figure 3).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These data revealed that varenicline (ED20∼0.12 mg kg–1) is about 20-fold more potent in increasing dopamine turn-over than cytisine (ED20∼2.5 mg kg–1), and at least 100-fold more potent than dianicline (ED20∼20 mg kg–1).”
- Also stated in: § Results · plain
“After oral administration, varenicline was found to be 20- and 100-fold more potent than cytisine and dianicline, respectively, in stimulating dopamine turn-over in rat nucleus accumbens (Figure 5).”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Moreover, there are very small differences in other molecular properties of the partial agonists that impact permeability and transport, and none of the compounds was found to be a substrate for P-gp or BCRP efflux transporters (Supporting Information Tables S2 and S3).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, there are substantial quantitative differences in binding affinities and functional potencies of dianicline versus the other two partial agonists, and much higher dianicline concentrations are required for an interaction with α4β2 nAChRs.”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As varenicline has moderate affinity for α7 nAChRs (Ki= 125 nM; Table 4), we are also investigating the interactions of varenicline with this receptor subtype.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Dianicline has comparable permeability and hydrophilicity as varenicline, and is not a substrate for P-gp or BCRP efflux transporters (Supporting Information Tables S2 and S3), but has limited brain penetration.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“At physiological pH, the partial agonists have approximately the same distribution coefficient (ElogD7.4), because at pH 7.4 much less cytisine, which has an acid dissociation constant (pKa) of 7.8, is in the protonated form than varenicline and dianicline (pKa 9.3–9.8; Supporting Information Table S3).”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Achieved abstinence rates and odds ratios (ORs) versus placebo are higher for varenicline (Cahill et al., 2008; Nides et al., 2008) than for either cytisine (Etter, 2006; Cahill et al., 2008) or dianicline (Fagerström and Balfour, 2006).”
What the sources say
- Not checked yetcites Cahill et al., 2008
- Not checked yetcites Nides et al., 2008
- Not checked yetcites Etter, 2006
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Compounds with reduced agonist efficacy at α4β2 nAChRs with a slower onset and much longer half-life than inhaled nicotine should exhibit a low potential for abuse liability.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“suggesting either overestimation of unbound brain exposures or active transport of both compounds into the brain or underestimation of CSF concentrations.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Additional nAChR subtypes, including α3*, α5* and α6* nAChRs, have been proposed to contribute to mesolimbic activity and nicotine dependence (Drenan et al., 2008; Exley et al., 2008; Pons et al., 2008; Grady et al., 2009; Livingstone et al., 2009; Ramiro et al., 2009).”
What the sources say
- Not checked yetcites Drenan et al., 2008
- Not checked yetcites Exley et al., 2008
- Not checked yetcites Pons et al., 2008
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Fluctuating nicotine concentrations in smokers, with a fast rising phase in seconds and a slow decline over hours, are expected to produce receptor activation followed by desensitization that likely contributes to the wide range of effects of nicotine (Picciotto et al., 2008).”
What the sources say
- Not checked yetcites Picciotto et al., 2008
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Finally, treatment with 40 mg BID dianicline is predicted to result in unbound brain concentrations of 40–80 nM, which will cause only minimal desensitization of α4β2 nAChRs.”
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This is likely insufficient to significantly reduce craving when quitting, and will only marginally reduce nicotine-evoked reinforcing effects.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- The authors state this as an assumption: Differences in functional interactions between the partial agonist and the α4β2 nAChR will result in varying degrees of relief of craving and attenuation of nicotine reinforcement, and hence in clinical efficacy.
In the paper
“These data (grey bars in Figure 3) show that unbound nicotine concentrations from tobacco smoking (50–300 nM; Rose et al., 1999) and varenicline concentrations after therapeutic doses (30–130 nM) will markedly, but not fully, desensitize the receptors.”
What the sources say
- Not checked yetcites Rose et al., 1999
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Working together, these properties result in a significant increase in efficacy over other treatments that do not meet these criteria, either because of insufficient CNS drug exposure at the target site or because of inadequate functional potency.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: The clinical outcome of treatment with partial agonists is determined both by their unbound human brain concentrations and their functional potencies at the target α4β2 nAChR.
- The authors state this as an assumption: Differences in functional interactions between the partial agonist and the α4β2 nAChR will result in varying degrees of relief of craving and attenuation of nicotine reinforcement, and hence in clinical efficacy.
None of the sources cited for this claim have been checked yet.
In the paper
“The poor brain penetration of cytisine has previously been attributed to its high hydrophilicity, that is, a lower logP value than nicotine and the other agonists (Reavill et al., 1990; Tutka and Zatoński, 2005; Supporting Information Table S3).”
What the sources say
- Not checked yetcites Reavill et al., 1990
- Not checked yetcites Tutka and Zatoński, 2005
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At therapeutic doses, varenicline is predicted to minimally desensitize α7 nAChRs and not causing detectable activation of this receptor.”
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In contrast, the low Bu for 1.5 mg QID cytisine (2–10 nM) is predicted to cause significant desensitization, but not α4β2 nAChR activation.”
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Functional data confirm that varenicline acts as a full α7 nAChR agonist (107% v ACh) (Mihalak et al., 2006), but at concentrations that are significantly higher than estimated human brain concentrations.”
What the sources say
- Not checked yetcites Mihalak et al., 2006
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“In addition to β2-containing subtypes, the α7 nAChR has been implicated in the effects of nicotine (Mansvelder and McGehee, 2002; Mansvelder et al., 2002).”
What the sources say
- Not checked yetcites Mansvelder and McGehee, 2002
- Not checked yetcites Mansvelder et al., 2002
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“A comparative meta-analysis of abstinence rates versus placebo at 6 months post-quit for available smoking cessation medications showed an estimated OR (95% CI) of 3.1 (2.5–3.8) for varenicline, while those for individual nicotine replacement therapies were 2.3 (1.7–3.0) or lower (Fiore et al., 2008).”
What the sources say
- Not checked yetcites Fiore et al., 2008
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The authors state this as an assumption.
Rat and human have the same brain-to-plasma ratio for each compound.
“assuming that rat and human have the same B/P ratio for each compound.”
The paper relies on this without support.
The clinical outcome of treatment with partial agonists is determined both by their unbound human brain concentrations and their functional potencies at the target α4β2 nAChR.
“As with other centrally acting drugs, the clinical outcome of treatment with partial agonists is determined both by their unbound human brain concentrations and their functional potencies at the target α4β2 nAChR, and our aim was to evaluate whether key pharmacokinetic and pharmacodynamic properties of the three partial agonists would have predicted differences in their clinical efficacies.”
The authors state this as an assumption.
Differences in functional interactions between the partial agonist and the α4β2 nAChR will result in varying degrees of relief of craving and attenuation of nicotine reinforcement, and hence in clinical efficacy.
“The translation of these data to the clinic is based on the hypothesis that differences in functional interactions between the partial agonist and the α4β2 nAChR will result in varying degrees of relief of craving and attenuation of nicotine reinforcement, and hence in clinical efficacy.”
The authors state this as an assumption.
The OR of dianicline is comparable to or lower than that of cytisine.
“Because in addition, further development of dianicline was halted in 2008 (Sanofi-Aventis press release, 2008), it is reasonable to assume that the OR of dianicline is comparable to or lower than that of cytisine.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Therefore, these results may be due to differential effects of varenicline and sazetidine-A on nAChR activation and desensitization (Caldarone et al, 2011; Rollema et al, 2010; Xiao et al, 2006; Zwart et al, 2008).”
From Divergent Functional Effects of Sazetidine-A and Varenicline During Nicotine Withdrawal (2013) · cites this paper as Rollema et al, 2010
In the citing paper
“recent evidence suggests that the therapeutic window for varenicline corresponds to the point at which there is enough unbound agonist to elicit combined desensitization and receptor activation (Rollema et al, 2010).”
From Divergent Functional Effects of Sazetidine-A and Varenicline During Nicotine Withdrawal (2013) · cites this paper as Rollema et al, 2010
In the citing paper
“In addition, deposition studies show that varenicline levels in brain following an acute administration remain in the low micromolar range for up to 6 h (Rollema et al, 2010).”
From Divergent Functional Effects of Sazetidine-A and Varenicline During Nicotine Withdrawal (2013) · cites this paper as Rollema et al, 2010
In the citing paper
“moreover, both the concentrations and the brain-to-blood ratios of nicotine and varenicline were similar to previously reported values (Ghosheh et al., 1999;Doura et al., 2008;Rollema et al., 2010).”
From Chronic Sazetidine-A at Behaviorally Active Doses Does Not Increase Nicotinic Cholinergic Receptors in Rodent Brain (2012) · cites this paper as Rollema et al., 2010
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Abstract
“recommended doses of cytisine, despite its high in vitro potency, are predicted to result in brain concentrations that are insufficient to affect α4β2 nAChRs.”
§ Results
“the low Bu for 1.5 mg QID cytisine (2–10 nM) is predicted to cause significant desensitization, but not α4β2 nAChR activation.”
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Results
“Cytisine is the only compound showing moderate affinity for the muscle α1-containing nAChRs (Ki= 430 nM)”
§ Results
“α1β1γδ ([ 3 H]-α bungarotoxin) 2090 ± 620 8200 ± 1530 492 ± 11 >12 500”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“It has 15-fold higher affinity than nicotine (Ki= 6.1 nM)”
Reported 15 · recomputed 40.25
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Results
“to be 36 and 216 nM, respectively (Table 3).”
§ Results
“Dianicline 2 × 40 14.1 3.3 2.7 0.82 1 214 37–84”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“it binds to this nAChR subtype with at least 20-fold higher affinity than the other compounds (Ki values > 2.1 µM).”
Reported 20 · recomputed 16.88
Citations
Cites
Treating Tobacco Use and Dependence
(2008) · PEDIATRICS · doi:10.1542/peds.2008-1627 · Cited by 2,701
Guide to receptors and channels (GRAC), 5th edition
Alexander, S., Mathie, A., & Peters, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01649_1.x · Cited by 1,947
Picciotto, M. R., Zoli, M., Rimondini, R., Léna, C., Marubio, L. M., Pich, E. M., Fuxe, K., & Changeux, J.-P. (1998) · Nature · doi:10.1038/34413 · Cited by 1,320
Treating tobacco use and dependence: 2008 update: Clinical practice guideline
(2008) · PsycEXTRA Dataset · doi:10.1037/e481882008-001 · Cited by 1,219
Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics
Benowitz, N. L. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094742 · Cited by 979
Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation
Coe, J. W., Brooks, P. R., Vetelino, M. G., Wirtz, M. C., Arnold, E. P., Huang, J., Sands, S. B., Davis, T. I., Lebel, L. A., Fox, C. B., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050069n · Cited by 930
Self-citationNicotine receptor partial agonists for smoking cessation
Hey, K., Lancaster, T., & Bala, M. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103 · Cited by 866
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L., & Lancaster, T. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub2 · Cited by 747
Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas
Mansvelder, H. D., Keath, J. R., & McGehee, D. S. (2002) · Neuron · doi:10.1016/s0896-6273(02)00625-6 · Cited by 701
Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors
Maskos, U., Molles, B. E., Pons, S., Besson, M., Guiard, B. P., Guilloux, J.-P., Evrard, A., Cazala, P., Cormier, A., Mameli-Engvall, M., et al. (2005) · Nature · doi:10.1038/nature03694 · Cited by 566 · cited 2×
“This is consistent with nAChR-mediated dopamine release being predominantly mediated via activation and desensitization of a4b2-containing nAChRs located on dopaminergic and GABAergic neurons (Picciotto et al., 1998; 2008; Mansvelder and McGehee, 2002; Mansvelder et al., 2002; Laviolette and Van der Kooy, 2004; Maskos…”
Background
Research works printed but not linked: 1
- Sanofi‐Aventis press release February 12 2008 p.14.http://en.sanofi‐aventis.com/press/press%20releases/2008/ppc14630.asp.
Cited by
Sorted by citations
Items 101–168 of 168
Attenuating nicotine’s effects with high affinity human anti-nicotine monoclonal antibodies
Raleigh, M. D., Beltraminelli, N., Fallot, S., LeSage, M. G., Saykao, A. T., Pentel, P. R., Fuller, S., Thisted, T., Biesova, Z., Horrigan, S. K., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0254247 · Cited by 10
Dean, B., Möller, H., Svensson, T. H., Geyer, M. A., Rujescu, D., Scarr, E., & Millan, M. J. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713001077 · Cited by 11
Nicotinic effects of tobacco smoke constituents in nonhuman primates
Desai, R. I., Doyle, M. R., Withey, S. L., & Bergman, J. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4238-5 · Cited by 11
“…c Anderson and Arneric (1994) d Xiao and Kellar (2004) e Marks et al. (1986) f Marks et al. (1996) g Decker et al. (1995) h Badio and Daly (1994) i Hahn et al. (2003) j Damaj et al. (1994) k Rollema et al. (2010) l Kem et al. (1997) m Ferretti et al. (2003) n Vainio and Tuominen (2001) hexagons).”
Characterization of Ultrapotent Chemogenetic Ligands for Research Applications in Nonhuman Primates
Raper, J., Eldridge, M. A. G., Sternson, S. M., et al. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00525 · Cited by 10
A New Radioligand Binding Assay to Measure the Concentration of Drugs in Rodent Brain Ex Vivo
Hussmann, G. P., & Kellar, K. J. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.198069 · Cited by 9
The role of nicotinic receptors in alcohol consumption
Kamens, H. M., Flarend, G., & Horton, W. J. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106705 · Cited by 8
Nicotine and Cytisine Embryotoxicity in the Experimental Zebrafish Model
Świątkowski, W., Budzyńska, B., Maciąg, M., Świątkowska, A., Tylżanowski, P., Rahnama, M., Stachurski, P., & Chałas, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512094 · Cited by 12
“These results suggest that cytisine has a limited ability to cross the blood-brain barrier (BBB) [31].”
BackgroundChen, Y., Broad, L. M., Phillips, K. G., & Zwart, R. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01628.x · Cited by 9
“Prolonged application of a4b2 partial agonists may, therefore, only persistently activate receptors over a narrow ‘window’ of concentrations where balance between activation and desensitization is achieved (Lester, 2004; Rollema et al., 2010; Papke et al., 2011).”
BackgroundGrebenstein, P. E., Harp, J. L., & Rowland, N. E. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.07.012 · Cited by 9
“Because of low brain concentrations of cytisine due to either possible increases in active brain efflux transporters (Rollema et al., 2010) or poor brain penetration (Reavill et al.”
BackgroundInfluentialWithey, S. L., Doyle, M. R., Bergman, J., & Desai, R. I. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.248070 · Cited by 9
“The effects of these compounds are consistent with their in vitro classification as nicotinic partial agonists at the a4b2 nAChR subtype (Kem et al., 1997; Hahn et al., 2003; Shoaib, 2006; Rollema et al., 2010).”
BackgroundGendy, M. N. S., Ibrahim, C., Sloan, M. E., & Foll, B. L. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_253 · Cited by 10
Enantiopure Cyclopropane-Bearing Pyridyldiazabicyclo[3.3.0]octanes as Selective ?4?2-nAChR Ligands
Onajole, O. K., Eaton, J. B., Lukas, R. J., Brunner, D., Thiede, L., Caldarone, B. J., & Kozikowski, A. P. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500129k · Cited by 8
A Review of the Organic Synthesis and Medicinal Applications of the Natural Product Cytisine
Bartusik‐Aebisher, D., Aebisher, D., & Tutka, P. (2016) · Modern Organic Chemistry Research · doi:10.22606/mocr.2016.11002 · Cited by 7
[ 125 I]Iodo-ASEM, a specific in vivo radioligand for α7-nAChR
Gao, Y., Mease, R. C., Olson, T. T., et al. (2014) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2014.12.008 · Cited by 8
(−)-Cytisine: Access to a stereochemically defined and functionally flexible piperidine scaffold
Niwetmarin, W., Campello, H. R., Sparkes, H. A., Aggarwal, V. K., & Gallagher, T. C. (2018) · Organic & Biomolecular Chemistry · doi:10.1039/c8ob01456f · Cited by 8
TC299423, a Novel Agonist for Nicotinic Acetylcholine Receptors
Wall, T. R., Henderson, B. J., Voren, G., Wageman, C. R., Deshpande, P., Cohen, B. N., Grady, S. R., Marks, M. J., Yohannes, D., Kenny, P. J., et al. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00641 · Cited by 8
Enhancement of alcohol aversion by the nicotinic acetylcholine receptor drug sazetidine‐A
Touchette, J. C., Moen, J. K., Robinson, J. M., & Lee, A. M. (2020) · Addiction Biology · doi:10.1111/adb.12908 · Cited by 6
“show that it is also a partial agonist at α3* and α6* receptors and a full agonist at α7 receptors [16, 25–27].”
BackgroundDebom, R. (2014) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000396 · Cited by 7
Ramotowski, B., & Budaj, A. (2021) · Kardiologia Polska · doi:10.33963/kp.a2021.0025 · Cited by 7
“Varenicline is a synthetic drug that binds to the same α4-β2 nAChR as cytisine and crosses the blood-brain barrier with a marked effect on the receptors [28].”
BackgroundNicotinic acetylcholine receptors-targeting drug discovery
Zhang, D., Zheng, H., Cui, K., Li, Y., Liu, C., Mao, J., Zheng, J., & Wan, Y. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118679 · Cited by 6
Quiroz, G., Sotomayor‐Zárate, R., González-Gutiérrez, J. P., Viscarra, F., Moraga, F., Bermúdez, I., Reyes-Parada, M. I., Quintanilla, M. E., Lagos, D., Rivera‐Meza, M., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01429 · Cited by 5
“Partial agonists of nAChRs such as cytisine (Papke and Heinemann, 1993; Rollema et al., 2010) and varenicline (Coe et al., 2005; Rollema et al., 2007) have been shown to decrease ethanol intake in rodents after a single dose or short-term administration (Steensland et al., 2007; Kamens et al.,…”
BackgroundChuang, Y.-H., Lee, C., Lin, C., et al. (2020) · Cancers · doi:10.3390/cancers12051324 · Cited by 5
Haarmann, H., Gossler, A., Herrmann, P., Bonev, S., Nguyen, X. P., Hasenfuss, G. P., Andreas, S., & Raupach, T. (2016) · Tobacco Induced Diseases · doi:10.1186/s12971-016-0091-x · Cited by 5
Varenicline: Smoking Cessation in Patients with Medical and Psychiatric Comorbidity
Tonstad, S., & Els, C. (2010) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s4012 · Cited by 5
Varenicline rescues nicotine-induced decrease in motivation for sucrose reinforcement
Hart, E. E., Hertia, D., Barrett, S. T., & Charntikov, S. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112887 · Cited by 3
Acetylcholine and Depression: Scrutinizing Future Therapeutic Targets for Novel Drug Development
Pannu, A. S., & Goyal, R. K. (2024) · Current Clinical Pharmacology · doi:10.2174/0127724328311930240907133618 · Cited by 5
DeBaker, M. C., Moen, J. K., Robinson, J. M., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/601641 · Cited by 4
Nichols, A. L., Marotta, C. B., Lukas, H., Friesenhahn, N. J., Wagenaar, D. A., Mayo, S. L., Dougherty, D. A., Benowitz, N. L., Gao, W. F., Muthusamy, A. K., et al. (2025) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntaf062 · Cited by 3
“73 Special intra-arterial [ 11 C]nicotine PET measurements in humans achieve a resolution of ~5 seconds, 4,6,58 which is unnecessary for most studies of [nicotine] t .”
Yu, L., Eaton, J. B., Zhang, H., Sabath, E. V., Hanania, T., Li, G., van Breemen, R. B., Whiteaker, P., Liu, Q., Wu, J., et al. (2014) · Pharmacology Research & Perspectives · doi:10.1002/prp2.26 · Cited by 3
Understanding varenicline function via key receptor and ligand interactions
Aiken, S., Fiorito, D., Harper, M., Pikus, G., Underhill, J., Murray, J., Rawlinson, J., O’Donoghue, A. C., Gotti, C., Lummis, S. C. R., et al. (2025) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2025.102992 · Cited by 3
Camilleri, M. (2026) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2026.03.038 · Cited by 2
Luque-Sanchez, K., Felix, J. S., Bilbrey, J. A., Restrepo, L., Reeves, M. E., McMahon, L. R., & Wilkerson, J. L. (2023) · Advances in Drug and Alcohol Research · doi:10.3389/adar.2023.11622 · Cited by 2
Xiong, X., Xiong, S., Zhu, R., Liu, S., Gao, F., & Chen, Y. (2025) · ACS Sensors · doi:10.1021/acssensors.5c00275 · Cited by 2
Gálvez, G., González-Gutiérrez, J. P., Hödar-Salazar, M., Sotomayor‐Zárate, R., Quintanilla, M. E., Quilaqueo, M. E., Rivera‐Meza, M., & Iturriaga‐Vásquez, P. (2022) · Biomedicines · doi:10.3390/biomedicines10071482 · Cited by 2
Dopaminergic Neurons in the Ventral Tegmental Area and Their Dysregulation in Nicotine Addiction
Dumont, G., Maex, R., & Gutkin, B. S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809825-7.00003-1 · Cited by 2
Radioiodinated 9-fluorenone derivatives for imaging α7-nicotinic acetylcholine receptors.
Gao, H., Wang, S.-X., Qiang, B., Wang, S.-X., & Zhang, H.-B. (2019) · MedChemComm · doi:10.1039/c9md00415g · Cited by 1
Quintanilla, M. E., Rivera‐Meza, M., Berríos‐Cárcamo, P., & Cassels, B. K. (2023) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2023.110900 · Cited by 4
Functional Distribution and Regulation of Neuronal Nicotinic ACh Receptors in the Mammalian Brain
Yakel, J. L. (2014) · The Receptors · doi:10.1007/978-1-4939-1167-7_5 · Cited by 2
Nichols, A. L., Blumenfeld, Z., Fan, C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.04.463082 · Cited by 2
Nichols, A. L., Marotta, C. B., Wagenaar, D. A., Mayo, S. L., Dougherty, D. A., & Lester, H. A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.02.625538 · Cited by 2
Research Progress in Pharmacological Effects of Cytisine
季, 宇. (2018) · Hans Journal of Medicinal Chemistry · doi:10.12677/hjmce.2018.64013 · Cited by 1
León, F., Zakid, A. A., Gupta, S., Mukhopadhyay, S., Tarawneh, A. H., Obeng, S., Cutler, S. J., & McCurdy, C. R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-95702-1.00490-5 · Cited by 1
An Open-Label Trial of Effects of Varenicline in Nonconstipation Irritable Bowel Syndrome and Pain
Matar, A., Busciglio, I. A., Eckert, D. J., Linden, D. R., Harmsen, W. S., & Camilleri, M. (2026) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2026.03.045 · Cited by 1
Current and Future Trends in Drug Discovery and Development Related to Nicotinic Receptors
Arnerić, S. P., & Sher, E. (2014) · The Receptors · doi:10.1007/978-1-4939-1167-7_21 · Cited by 1
Effect of MDR C3435T polymorphism on Varenicline treatment in quit smoking
Bozkurt, N., Altıntaş, F., Bozkurt, A. İ., Turgut, G., & Turgut, S. (2019) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s2175-97902019000118186 · Cited by 1
“According to Rollema (2010), Varenicline is neither a substrate nor an inhibitor of P-gp.”
BackgroundEnhancement of alcohol aversion by the nicotinic acetylcholine receptor drug sazetidine-APreprint
Touchette, J. C., Moen, J. K., Robinson, J. M., & Lee, A. M. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/723916 · Cited by 1
Characterization of ultrapotent chemogenetic ligands for research applications in non-human primatesPreprint
Raper, J., Eldridge, M. A. G., Sternson, S. M., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.06.475241 · Cited by 1
“Another drawback is that, despite there being several ligands to activate DREADDs, each has at least some degree of off-target binding(Ilg et al., 2018; MacLaren et al., 2016; Manvich et al., 2018; Roseboom et al., 2021; Upright and Baxter, 2020).”
BackgroundHow Varenicline Works: Identifying Critical Receptor and Ligand-based InteractionsPreprint
Aiken, S., Fiorito, D., Harper, M., Pikus, G., Underhill, J., Murray, J., Rawlinson, J., O’Donoghue, A. C., Gotti, C., Lummis, S. C. R., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.14.659675 · Cited by 1
Pharmakologische und nicht-pharmakologische Effekte auf die Kognition
Both, C. (2013) · Univ. Duesseldorf: Duesseldorfer Dokumenten- und Publikationsserver
Hendrickson, L. M. (2011) · PubMed · doi:10.13028/174w-zb21
“…and behavioral experiments, varenicline doses were chosen based on previous studies of varenicline effects on nicotine selfadministration and DA turnover in addition to predicted therapeutic concentrations achieved in smokers’ brains (O'Connor et al., 2010; Rollema et al., 2010).”
BackgroundMethodInfluentialDevelopment of Antidepressant Drugs Through Targeting α4β2-Nicotinic Acetylcholine Receptors
Zhang, H., Gunosewoyo, H., Fan, Y., Tang, J., & Yu, L.-F. (2016) · Neuromethods · doi:10.1007/978-1-4939-3768-4_11
The Effects of Binge-Like Sucrose Consumption on the Mesolimbic Reward Pathway in the Brain
Shariff, M. R. (2017) · Queensland University of Technology · doi:10.5204/thesis.eprints.107900
Nicotine and Cardiovascular Function
Ialongo, C., Sabatini, D., & Grassi, M. (2019) · Springer eBooks · doi:10.1007/978-3-319-90305-7_52-1
Varenicline rescues nicotine-induced decrease in motivation for sucrose reinforcementPreprint
Hart, E. E., Hertia, D., Barrett, S. T., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.03.129791
“Likewise, the varenicline desensitizes nicotinic acetylcholine receptors (Rollema et al., 2010) and this effect may explain long-term effects we observed in our study.”
Sugar consumption and expression of neuronal nicotinic receptors in the Nucleus Accumbens
Ali, S. A. (2021) · Queensland University of Technology · doi:10.5204/thesis.eprints.208972
Nicotine and Cardiovascular Function
Ialongo, C., Sabatini, D., & Grassi, M. (2020) · Springer eBooks · doi:10.1007/978-3-030-28008-6_52 · Cited by 2
Potential uses of cytisine for smoking cessation in menopausal women – literature summary
Rubio, F. I. R., Martínez, F., & Zarzuelo-Romero, M. J. (2023) · Menopause Review/Przegląd Menopauzalny · doi:10.5114/pm.2023.126439
Clearing the air: methods and challenges of smoking and vaping cessation
van Nieuwenhuizen, T. J., Schellack, N., Bronkhorst, E., & Savides, I. A. (2025) · SA pharmaceutical journal. · doi:10.36303/sapj.2550
Castedo, C. R., Estany‐Gestal, A., Ruiz, C. A. J., et al. (2025) · doi:10.2196/preprints.76815
Przybył, A. K., Huczyński, A., & Krystkowiak, E. (2025) · Molecules · doi:10.3390/molecules30193955
Cholinergic regulation of prolonged alcohol withdrawal differs by sexPreprint
Payne, N., Scott, S., Scalf, M., Dobbelmann, R., Engel, S., & Lee, A. M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.12.693968
“Mecamylamine is a non-specific nicotinic acetylcholine receptor (nAChR) antagonist that affects all nAChR subtypes, whereas varenicline is a partial agonist at the a 4 b 2 and a 3-containing nAChR subtypes [36,37], and a full agonist at a 7 nAChRs [38].”
Castedo, C. R., Estany‐Gestal, A., Ruiz, C. A. J., de Granda‐Orive, J. I., Riesco, J. A., Fernández, M. I. C., Pinedo, Á. R., Signes‐Costa, J., Unzueta, M. I. G., Morales, A. S. V., et al. (2025) · JMIR Research Protocols · doi:10.2196/76815
“Current scientific evidence has shown it to be a safe and effective smoking cessation molecule [5].”
Nichols, A. L., Marotta, C. B., Friesenhahn, N. J., Dalfonzo, S. R., Muthusamy, A. K., Wagenaar, D. A., Mayo, S. L., Dougherty, D. A., & Lester, H. A. (2025) · ACS Applied Bio Materials · doi:10.1021/acsabm.5c01418 · Cited by 2
Nerella, S. G., Liow, J., Li, B., Jenson, A. E. S., Pamie-George, M. T., Zoghbi, S. S., Gomez, J. L., Michaelides, M., Magnus, C., Sternson, S. M., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02679
The role of cytisinicline in the treatment of nicotine dependence
Slíva, J. (2026) · Medicína pro praxi · doi:10.36290/med.2026.018
Li, X., Zeng, L.-L., Jiang, X.-Q., Yao, J., Song, L.-J., Xu, J.-H., Teng, J.-F., Liu, S., Wu, B., & Hu, K.-H. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00860
Neuropharmacology of Nicotine Addiction and Therapeutic Strategies for Smoking Cessation
Hefny, A. A., Karuturi, R. C., Kalyaanamoorthy, S., Rao, P. P. N., & Ganesan, A. (2026) · Biology · doi:10.3390/biology15161412
“[129].”
Regulation of Neuronal Nicotinic Receptor Expression by Novel Ligands and Mechanisms
Hussmann, G. P. (2012) · DigitalGeorgetown (Georgetown University Library)
Metadata
- Authors
- Rollema, H., Shrikhande, A., Ward, K., Tingley III, F., Coe, J., O'Neill, B., Tseng, E., Wang, E., Mather, R., Hurst, R., Williams, K., de Vries, M., Cremers, T., Bertrand, S., & Bertrand, D.
- Affiliations
- Pfizer (United States) (US)
- University of Groningen (NL)
- HiQScreen (Switzerland) (CH)
- University of Geneva (CH)
- Corresponding author
- Rollema, H
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2010-04-26
- Volume
- 160
- Issue
- 2
- Pages
- 334-345
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- PMC
- PMC2874855
- OpenAlex
- W2165094621
- Semantic Scholar
- 1191629a1b48d758592ada45966ec228976b716d
- Cited by
- 162
- References
- 49
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 2 · 2023: 8 · 2022: 4 · 2021: 8 · 2020: 6 · 2019: 13 · 2018: 6 · 2017: 7 · 2016: 8 · 2015: 9 · 2014: 20 · 2013: 18 · 2012: 18
- FWCI
- 7.29
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- British Journal of Pharmacology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Funders
- Pfizer
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Alkaloids: synthesis and pharmacology
- Keywords
- varenicline, cytisine, α4β2 nicotinic acetylcholine receptor, partial agonists, nicotine dependence, smoking cessation, brain pharmacokinetics, receptor desensitization, receptor activation, brain penetration
- MeSH terms
- Varenicline, Quinolizidine Alkaloids, ATP-Binding Cassette Sub-Family B Member 4, Alkaloids, Animals, Azepines, Azocines, Benzazepines, Brain, Dopamine, Heterocyclic Compounds, 4 or More Rings, Humans, Limbic System, Male, Quinolizines, Quinoxalines, Receptors, Nicotinic, Tissue Distribution, Tobacco Use Disorder, Xenopus laevis, Smoking Cessation, Rats, Sprague-Dawley, Mice, Knockout, ATP Binding Cassette Transporter, Subfamily B, Nicotinic Agonists, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
